Similar articles

Abstract: In order to comply with the requirements for a drug listed in China, the study was developed to compare the pharmacokinetics and relative bioavailability of two different enteric formulations of omeprazole (OPZ) in healthy Chinese subjects. A total of 32 volunteers participated in the study. Plasma concentrations were analyzed by nonstereospecific liquid chromatography/tandem mass spectrometric (LC-MS/MS) method. After administration of a single 40-mg dose of the two OPZ formulations, the comparative bioavailability was assessed by calculating individual AUC_0‒t (the area under the concentration-time curve from time zero to the last measurable concentration), AUC_0‒∞ (the area under the concentration-time curve extrapolated to infinity), C_max (the maximum observed concentration), and T_peak (the time to C_max) values of OPZ, 5-hydroxyomeprazole (OH-OPZ), and omeprazole sulfone (OPZ-SFN), respectively. The 90% confidence intervals (CIs) of AUC_0‒t, AUC_0‒∞, and C_max were 85.4%‒99.0%/88.8%‒98.6%/87.6%‒99.4%, 85.5%‒99.2%/89.0%‒98.6%/88.5%‒101.3%, and 72.3%‒87.6%/79.6%‒91.1%/88.4%‒99.1% for OPZ/OH-OPZ/OPZ-SFN, respectively, and T_peak values did not differ significantly. In this study, the test formulation of OPZ in fasting healthy Chinese male volunteers met the Chinese bioequivalance standard to the reference formulation based on AUC, C_max, and T_peak.

[1]Allegrini, A., Nuzzo, L., Scaringi, A.T., Felaco, S., Pavone, D., Toniato, E., Mezzetti, A., Martinotti, S., Lenotti, G., 2008. Bioequivalence study of two capsule formulations of omeprazole in healthy volunteers. Arzneimittelforschung, 58(8):385-388.

[2]Andersson, T., Regårdh, C.G., Lou, Y.C., Zhang, Y., Dahl, M.L., Bertilsson, L., 1992. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics, 2(1):25-31.

[3]Andersson, T., Miners, J.O., Veronese, M.E., Birkett, D.J., 1994. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol., 37(6):597-604.

[4]Bertilsson, L., Lou, Y.Q., Du, Y.L., Liu, Y., Kuang, T.Y., Liao, X.M., Wang, K.Y., Reviriego, J., Iselius, L., Sjöqvist, F., 1992. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther., 51(4):388-397.

[5]Blum, R.A., 1996. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am. J. Health Syst. Pharm., 53(12):1401-1415.

[6]Bolton, S., 1997. Pharmaceutical Statistics: Practical and Clinical Applications, 3rd Ed. Marcel Dekker, New York, USA, p.210-212, 405-418.

[7]Hu, X.P., Xu, J.M., Hu, Y.M., Mei, Q., Xu, X.H., 2007. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J. Clin. Pharm. Ther., 32(5):517-524.

[8]Joti, J.J., Nahar, K., Hasan, A., Azad, M.A., Ullah, M.A., Islam, S.M., Hasnat, A., 2009. Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers. Arzneimittelforschung, 59(4):171-175.

[9]Kanazawa, H., Okada, A., Higaki, M., Yokota, H., Mashige, F., Nakahara, K., 2003. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. J. Pharm. Biomed. Anal., 30(6):1817-1824.

[10]Poo, J.L., Galán, J.F., Rosete, A., de Lago, A., Oliva, I., González-de la Parra, M., Jiménez, P., Burke-Fraga, V., Namur, S., 2008. Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers. Clin. Ther., 30(4):693-699.

[11]Rambla-Alegre, M., Esteve-Romero, J., Carda-Broch, S., 2009. Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases. Anal. Chim. Acta, 633(2):250-256.

[12]Rezk, N.L., Brown, K.C., Kashuba, A.D., 2006. A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure. J. Chromatogr. B, 844(2):314-321.

[13]Rhim, S.Y., Park, J.H., Park, Y.S., Lee, M.H., Hwang, K.G., Kim, Y.S., Shaw, L.M., Lee, Y.S., Kang, J.S., 2009. Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. Int. J. Clin. Pharmacol. Ther., 47(1):23-29.

[14]Sachs, G., Shin, J.M., Howden, C.W., 2006. Review article: the clinical pharmacology of proton pump inhibitors. Aliment. Pharmacol. Ther., 23 (S2):2-8.

[15]SFDA (State Food and Drug Administration of China), 2003. Guideline for Good Clinical Practice (in Chinese). Available from http://www.sda.gov.cn/WS01/CL0053/ 24473.html [Accessed on Feb. 10, 2009].

[16]SFDA (State Food and Drug Administration of China), 2005. Guideline for Bioavailability and Bioequivalence Studies of Generic Drug Products (in Chinese). Available from http://www.cde.org.cn/zdyz.do?method=largePage&id=2066 [Accessed on Feb. 10, 2009].